Date: 2012-01-20
Type of information: Co-promotion agreement
Compound: Afirma® Thyroid FNA Analysis
Company: Genzyme (USA - MA), a Sanofi company (France) - Veracyte (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: co-promotion
Action mechanism: Veracyte’s novel solution combines expert cytopathology assessment of thyroid nodule FNA samples, with the company’s Afirma Gene Expression Classifier used to resolve indeterminate results and thus help patients with benign nodules avoid unnecessary surgery. Two independent clinical studies – both part of a large, multicenter, prospective clinical trial involving academic and community sites – have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as “benign” with the same degree of accuracy as a benign cytopathology diagnosis. Veracyte announced recently that its Afirma Gene Expression Classifier has been granted coverage for Medicare patients nationwide.
Disease: thyroid cancer
Details: Genzyme, a Sanofi company and Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, have announced a global co-promotion partnership to provide a comprehensive solution for thyroid patients.
The arrangement will give patients worldwide increased access to an advanced personalized medicine solution for improved diagnosis of thyroid nodules, and the potential to significantly reduce the number of unnecessary thyroidectomies.
Under terms of the agreement, Genzyme will market and promote Veracyte’s Afirma® Thyroid FNA Analysis, an innovative and novel approach for improved thyroid nodule diagnosis, in the United States and, subsequently, in global markets.
Financial terms: Financial terms of the deal were not disclosed.
Latest news:
